Results from second clinical trial of GSK's H1N1 adjuvanted vaccine confirm immune response and tolerability
GlaxoSmithKline (GSK) announced results from a second clinical trial of its pandemic (H1N1) adjuvanted vaccine, which demonstrate that one dose of the vaccine can provide a strong immune response which exceeds criteria as defined by international licensing authorities using the lowest dose of antigen available in pandemic vaccines. The data from GSK's H1N1 trials announced to date demonstrate the vaccine is generally well tolerated.
Read more ...
AstraZeneca Submits Marketing Authorisation Application to European Union for VIMOVO™
AstraZeneca and POZEN Inc. have submitted a Marketing Authorisation Application (MAA) in the European Union via the Decentralised Procedure (DCP) for VIMOVO™ (enteric-coated naproxen/immediate release esomeprazole magnesium, formerly known as PN 400) tablets, a product under investigation for the treatment of the signs and symptoms of osteoarthritis (OA), rheumatoid arthritis (RA) and ankylosing spondylitis (AS) in patients who are at risk of developing NSAID-associated ulcers.
Read more ...
Pfizer And Wyeth Become One: Working Together For A Healthier World™
Pfizer Inc (NYSE: PFE) today announced that it has combined operations with Wyeth following the closing of the acquisition yesterday. Pfizer is now a more diversified health care company, with product offerings in human, animal, and consumer health, including vaccines, biologics, small molecules and nutrition across the developed and emerging markets. It has medicines in numerous growing therapeutic areas, a robust pipeline, premier scientific and manufacturing capabilities and a leading global presence.
Read more ...
Roche reports further accelerated sales growth in third quarter
The Roche Group recorded sustained strong sales growth in the first nine months of 2009. Group sales grew 11% in local currencies (9% in Swiss francs; 4% in US dollars) to 36.4 billion Swiss francs. The Pharmaceuticals Division’s sales increased 12% in local currencies (11% in Swiss francs; 6% in US dollars) to 29.0 billion Swiss francs, maintaining growth at twice the global market rate.
Read more ...
GSK partners with UK Government and Wellcome Trust to stimulate innovation
GlaxoSmithKline plc (GSK) has entered into a unique partnership with the UK Government, The Wellcome Trust and the East of England Development Agency (EEDA) to develop an innovative new biotechnology science park located at GSK's site at Stevenage. The project aims to create a world-leading hub for early-stage biotechnology companies.
Read more ...
Boehringer Ingelheim receives approval from the European Commission for Mirapexin®/Sifrol
Boehringer Ingelheim announced that the Mirapexin®/Sifrol® (pramipexole) new prolonged-release, once daily tablet has been granted marketing authorisation by the European Commission in all EU/EEA) countries for the treatment of early and advanced idiopathic Parkinson's disease (PD). The approval was based on the submission of clinical trial results showing that the new formulation can offer an efficacy and safety profile comparable to the immediate release tablet taken three times daily.(1-6)
Read more ...
Panenza® and Humenza® Influenza A(H1N1) Vaccines Demonstrate Robust Immune Response After One Dose
Sanofi Pasteur, the vaccines division of the sanofi-aventis Group (EURONEXT: SAN and NYSE: SNY), announced that a single dose of influenza A (H1N1) 2009 monovalent vaccines, Panenza® (15 mcg dose, non-adjuvanted) or Humenza® (3.8 mcg dose, adjuvanted), administered to children (3 years of age and older) and adults induces a robust immune response, according to results from clinical trials conducted in Europe.
Read more ...